Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 13/20 | 0.58 |
| ▸ | TACR2 | P21452 | 9/20 | 0.58 |
| ▸ | TRPV4 | Q9HBA0 | 7/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776099 | 0.99 | TACR3 (0.59) | TACR3TACR2TRPV4OPRM1 | |
| SCHEMBL4776384 | 0.92 | TACR3 (0.53) | TACR3TACR2TRPV4OPRM1 | |
| SCHEMBL5001051 | 0.91 | TACR3 (0.57) | TACR3TACR2TRPV4OPRM1 | |
| SCHEMBL5001148 | 0.89 | TACR3 (0.73) | TACR3TACR2OPRM1 | |
| SCHEMBL4667098 | 0.89 | TACR3 (0.73) | TACR3TACR2OPRM1 | |
| SCHEMBL4665280 | 0.88 | TACR3 (0.71) | TACR3TACR2OPRM1 | |
| SCHEMBL4665958 | 0.87 | TACR3 (0.55) | TACR3TACR2OPRM1 | |
| SCHEMBL4665293 | 0.86 | TACR3 (0.54) | TACR3TACR2OPRM1 | |
| SCHEMBL4665284 | 0.86 | TACR3 (0.66) | TACR3TACR2 | |
| SCHEMBL4996159 | 0.85 | TACR3 (0.65) | TACR3TACR2TRPV4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | claimed |
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | claimed |
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | TACR3, TACR2, KCNA3 | TACR3 1/4885TACR2 2/4885TRPV4 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.